Effect of Intraoperative IV Ketamine on Postoperative Morphine Consumption During Intestinal Surgery

Effect of Intraoperative IV Ketamine on Postoperative Morphine Consumption During Intestinal Surgery and Its Effect on Salivary Cortisol and Alpha Amylase Levels

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03344393

Enrollment

Registered

2017-11-17

Start date

2017-12-01

Completion date

2019-03-01

Last updated

2017-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Analgesia

Brief summary

.The aim of this study is to identify the analgesic effect of intraoperative ketamine intravenous infusion on patients undergoing intestinal surgery and its effect on salivary cortisol and alpha amylase levels as indicator of its effect.

Detailed description

I- Group K (ketamine): 30 patients will receive intraoperative intravenous ketamine infusion. II- Group C (control): 30 patients will receive intraoperative intravenous normal saline infusion.

Interventions

DRUGKetamine Hydrochloride

intravenous ketamine infusion intraoperatively

DRUGNormal saline

intravenous normal saline infusion intraoperatively

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* \- Patient's status ASA status-I and II. * Patients age above 18 years old. * Patients scheduled for intestinal surgery.

Exclusion criteria

* Patient refusal. * Patients with known allergy to ketamine or morphine. * Patients with significant hepatic dysfunction. * Patients with severe renal disease. * Significant Heart disease. * Patients with chronic pain. * Regular use analgesics, antidepressants or opioids in last 2 months. * Any known convulsive disorder. * Morbid obesity (BMI\>35). * Patients with autoimmune disease * Patients on corticosteroid therapy * Pregnancy. * Breast feeding. * Woman under hormonal treatment. * Oral disease.

Design outcomes

Primary

Measure	Time frame	Description
morphine consumption	2 days postoperative	IV PCA

Secondary

Measure	Time frame	Description
cortisol level	2 days postoperative	salivary
alpha amylase level	2 days postoperative	salivary

Contacts

Primary Contactmohamed aly, MD

galalm1967@yahoo.com00201062011126

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026